Candel Therapeutics Inc (CADL)vsVertex Pharmaceuticals Inc (VRTX)
CADL
Candel Therapeutics Inc
$10.59
+0.09%
HEALTHCARE · Cap: $766.41M
VRTX
Vertex Pharmaceuticals Inc
$496.07
+2.49%
HEALTHCARE · Cap: $121.26B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 40603774% more annual revenue ($12.59B vs $31,000). VRTX leads profitability with a 35.0% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 64/100 (C+).
CADL
Avoid22
out of 100
Grade: F
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CADL.
Margin of Safety
+50.1%
Fair Value
$971.64
Current Price
$496.07
$475.57 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CADL
The strongest argument for CADL centers on Debt/Equity.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : CADL
The primary concerns for CADL are Revenue Growth, EPS Growth, Market Cap.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
CADL profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
VRTX carries more volatility with a beta of 0.30 — expect wider price swings.
VRTX is growing revenue faster at 12.5% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (64/100 vs 22/100), backed by strong 35.0% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Candel Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Candel Therapeutics Inc. is a pioneering biotechnology company focused on revolutionizing cancer treatment through its proprietary oncolytic virus platform, which uniquely targets and destroys cancer cells while preserving healthy tissue. The company has developed a promising pipeline that addresses several challenging malignancies, enhancing the body’s immune response against tumors and striving for significant advancements in therapeutic efficacy. With a solid intellectual property foundation and strategic collaborations with leading research institutions, Candel is well-positioned to be at the forefront of groundbreaking innovations in oncology, with the ultimate goal of improving patient outcomes and reshaping cancer care standards.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?